Rationale of combination therapy with antioxidants in medical management of Peyronie’s disease: results of clinical application

References

• SchwarzerUSommerFKlotzTBraunMReifenrathBEngelmannUThe prevalence of Peyronie’s disease: results of a large surveyBJU Int200188772773011890244
   PubMed Web of Science ®Google Scholar
• DibenedettiDBNguyenDZografosLZiemieckiRZhouXA population-based study of Peyronie’s disease: prevalence and treatment patterns in the United StatesAdv Urol2011201128250322110491
   PubMedGoogle Scholar
• PaulisGRomanoGPaulisAPrevalence, psychological impact, and risk factors of erectile dysfunction in patients with Peyronie’s disease: a retrospective analysis of 309 casesRes Rep Urol201689510327486570
   PubMedGoogle Scholar
• RompelRMueller-EckhardtGSchroeder-PrintzenIWeidnerWHLA antigens in Peyronie’s diseaseUrol Int199452134378140677
   PubMed Web of Science ®Google Scholar
• DolmansGHWerkerPMde JongIJLifeLines Cohort StudyWNT2 locus is involved in genetic susceptibility of Peyronie’s diseaseJ Sex Med2012951430143422489561
   PubMed Web of Science ®Google Scholar
• JarowJPLoweFCPenile trauma: an etiologic factor in Peyronie’s disease and erectile dysfunctionJ Urol19971584138813909302127
   PubMed Web of Science ®Google Scholar
• DevineCJJrSomersKDJordanSGSchlossbergSMProposal: trauma as a cause of Peyronie’s lesionJ Urol199715712852908976281
   PubMed Web of Science ®Google Scholar
• CampbellJAlzubaidiRUnderstanding the cellular basis and pathophysiology of Peyronie’s disease to optimize treatment for erectile dysfunctionTransl Androl Urol201761465928217450
   PubMed Web of Science ®Google Scholar
• GaraffaGTrostLWSerefogluECRalphDHellstromWJUnderstanding the course of Peyronie’s diseaseInt J Clin Pract201367878178823869679
   PubMed Web of Science ®Google Scholar
• LevineLALarsenSDiagnosis and management of Peyronie diseaseWeinAJKavoussiLRPartinAWPetersCACampbell-Walsh Urology11th edPhiladelphiaElsevier Saunders2015722748
   Google Scholar
• HatzimouratidisKGiulianoFMoncadaIEuropean Association of UrologyEAU Guidelines on Erectile Dysfunction, Premature Ejaculation, Penile Curvature and Priapism (Peyronie’s Disease Management, non-operative treatment, paragraph 3.3.2.3.11342016 Available from: https://uroweb.org/wp-content/uploads/EAU-Extended-Guidelines-2016-Edn.pdfAccessed February 26, 2017
   Google Scholar
• HellstromWJBivalacquaTJPeyronie’s disease: etiology, medical, and surgical therapyJ Androl200021334735410819440
   PubMed Web of Science ®Google Scholar
• HauckEWDiemerTSchmelzHUWeidnerWA critical analysis of nonsurgical treatment of Peyronie’s diseaseEur Urol200649698799716698449
   PubMed Web of Science ®Google Scholar
• GelbardMGoldsteinIHellstromWJClinical efficacy, safety and tolerability of collagenase clostridium histolyticum for the treatment of Peyronie disease in 2 large double-blind, randomized, placebo controlled phase 3 studiesJ Urol2013190119920723376148
   PubMed Web of Science ®Google Scholar
• Martínez-SalamancaJIEguiAMoncadaIAcute phase Peyronie’s disease management with traction device: a nonrandomized prospective controlled trial with ultrasound correlationJ Sex Med201411250651524261900
   PubMed Web of Science ®Google Scholar
• RajasekaranMHellstromWJSikkaSCNitric oxide induces oxidative stress and mediates cytotoxicity to human cavernosal cells in cultureJ Androl2001221343911191085
   PubMedGoogle Scholar
• SikkaSCHellstromWJRole of oxidative stress and antioxidants in Peyronie’s diseaseInt J Impot Res200214535336012454686
   PubMed Web of Science ®Google Scholar
• Gonzalez-CadavidNFMageeTRFerriniMQianAVernetDRajferJGene expression in Peyronie’s diseaseInt J Impot Res200214536137412454687
   PubMed Web of Science ®Google Scholar
• MorelandRBNehraAPathophysiology of Peyronie’s diseaseInt J Impot Res200214540641012454693
   PubMed Web of Science ®Google Scholar
• BivalacquaTJChampionHCHellstromWJImplications of nitric oxide synthase isoforms in the pathophysiology of Peyronie’s diseaseInt J Impot Res200214534535212454685
   PubMed Web of Science ®Google Scholar
• DavilaHHMageeTRVernetDRajferJGonzalez-CadavidNFGene transfer of inducible nitric oxide synthase complementary DNA regresses the fibrotic plaque in an animal model of Peyronie’s diseaseBiol Reprod20047151568157715240426
   PubMed Web of Science ®Google Scholar
• Gonzalez-CadavidNFRajferJMechanisms of disease: new insights into the cellular and molecular pathology of Peyronie’s diseaseNat Clin Pract Urol20052629129716474811
   PubMedGoogle Scholar
• El-SakkaAISalabasEDinçerMKadiogluAThe pathophysiology of Peyronie’s diseaseArab J Urol201311327227726558092
   PubMedGoogle Scholar
• Lemourt OlivaMFilgueiras LópezERodríguez BarrosoAGonzález OramasEBordonadoRClinical evaluation of the use of propoleum in Peyronie’s diseaseArch Esp Urol19985121711769586317
   PubMedGoogle Scholar
• Lemourt OlivaMFragas ValdésRBordonado RamírezRSantanaJLGonzález OramasEMerinoAPeyronie’s disease. Evaluation of 3 therapeutic modalities: propoleum, laser and simultaneous propoleum-laserArch Esp Urol200558993193516430041
   PubMedGoogle Scholar
• CavalliniGBiagiottiGKoverechAVitaliGOral propionyl-l-carnitine and intraplaque verapamil in the therapy of advanced and resistant Peyronie’s diseaseBJU Int200289989590012010235
   PubMed Web of Science ®Google Scholar
• BiagiottiGCavalliniGAcetyl-L-carnitine vs tamoxifen in the oral therapy of Peyronie’s disease: a preliminary reportBJU Int2001881636711446848
   PubMed Web of Science ®Google Scholar
• LinGShindelAWBanieLPentoxifylline attenuates transforming growth factor-beta1-stimulated elastogenesis in human tunica albuginea-derived fibroblasts part 2: interference in a TGF-beta1/Smad-dependent mechanism and downregulation of AAT1J Sex Med2010751787179720384945
   PubMed Web of Science ®Google Scholar
• ShindelAWLinGNingHPentoxifylline attenuates transforming growth factor-β1-stimulated collagen deposition and elastogenesis in human tunica albuginea-derived fibroblasts part 1: impact on extracellular matrixJ Sex Med2010762077208520367772
   PubMed Web of Science ®Google Scholar
• SafarinejadMRSafety and efficacy of coenzyme Q10 supplementation in early chronic Peyronie’s disease: a double-blind, placebo-controlled randomized studyInt J Impot Res201022529830920720560
   PubMed Web of Science ®Google Scholar
• BrantWODeanRCLueTFTreatment of Peyronie’s disease with oral pentoxifyllineNat Clin Pract Urol20063211111516470210
   PubMedGoogle Scholar
• SmithJFShindelAWHuangYCPentoxifylline treatment and penile calcifications in men with Peyronie’s diseaseAsian J Androl201113232232521102473
   PubMed Web of Science ®Google Scholar
• Dell’AttiLUghiGEfficacy of pentoxifylline in Peyronie’s disease: clinical case of a young manArch Ital Urol Androl201486323723825308598
   PubMedGoogle Scholar
• CiociolaFColpiGMPeyronie’s disease: a “triple oxygenant therapy”Arch Ital Urol Androl2013851364023695404
   PubMedGoogle Scholar
• AlizadehMKarimiFFallahMREvaluation of verapamil efficacy in Peyronie’s disease comparing with pentoxifyllineGlob J Health Sci201467 Spec233025363175
   PubMedGoogle Scholar
• FavillaVRussoGIPriviteraSCombination of intralesional verapamil and oral antioxidants for Peyronie’s disease: a prospective, randomised controlled studyAndrologia201446893694224124921
   PubMed Web of Science ®Google Scholar
• PaulisGD’AscenzoRNupieriPEffectiveness of antioxidants (propolis, blueberry, vitamin E) associated with verapamil in the medical management of Peyronie’s disease: a study of 151 casesInt J Androl201235452152721950543
   PubMedGoogle Scholar
• PaulisGCavalliniGBrancatoTAlvaroRPeironimev-Plus® in the treatment of chronic inflammation of tunica albuginea (Peyronie’s disease). Results of a controlled studyInflamm Allergy Drug Targets2013121616723004005
   PubMedGoogle Scholar
• PaulisGCavalliniGGiorgioGDQuattrocchiSBrancatoTAlvaroRLong-term multimodal therapy (verapamil associated with propolis, blueberry, vitamin E and local diclofenac) on patients with Peyronie’s disease (chronic inflammation of the tunica albuginea). Results of a controlled studyInflamm Allergy Drug Targets201312640340924304332
   PubMedGoogle Scholar
• PaulisGBarlettaDTurchiPEfficacy and safety evaluation of pentoxifylline associated with other antioxidants in medical treatment of Peyronie’s disease: a case-control studyRes Rep Urol2015811026770906
   PubMedGoogle Scholar
• AbernMRLarsenSLevineLACombination of penile traction, intralesional verapamil, and oral therapies for Peyronie’s diseaseJ Sex Med20129128829522024053
   PubMed Web of Science ®Google Scholar
• LamprakopoulosAZorzosILykourinasMThe use of betamethasone and yaluronidase injections in the treatment of Peyronie’s diseaseScand J Urol Nephrol200034635536011195899
   PubMed Web of Science ®Google Scholar
• Prieto CastroRMLeva VallejoMERegueiro LopezJCAnglada CuradoFJAlvarez KindelanJRequena TapiaMJCombined treatment with vitamin E and colchicine in the early stages of Peyronie’s diseaseBJU Int200391652252412656907
   PubMed Web of Science ®Google Scholar
• Candebat MonteroLHMiranda ReyesPLDíaz GarcíaFGonzález FerroIBarbosa RamosFCodorniu FuretJPeyronie’s disease: treatment with interferon and laserArch Esp Urol2008613413423 Spanish18581679
   PubMedGoogle Scholar
• CakanMDemirelFAldemirMAltugUDoes smoking change the efficacy of combination therapy with vitamin E and colchicines in patients with early-stage Peyronie’s disease?Arch Androl2006521212716338865
   PubMedGoogle Scholar
• ParkTYJeongHGParkJJThe efficacy of medical treatment of Peyronie’s disease: potassium para-aminobenzoate monotherapy vs. combination therapy with tamoxifen, L-carnitine, and phosphodiesterase type 5 inhibitorWorld J Mens Health2016341404627169128
   PubMedGoogle Scholar
• TaylorFLLevineLANon-surgical therapy of Peyronie’s diseaseAsian J Androl2008101798718087647
   PubMed Web of Science ®Google Scholar
• KuehhasFEWeiblPGeorgiTDjakovicNHerwigRPeyronie’s disease: nonsurgical therapy optionsRev Urol201113313914622110397
   PubMedGoogle Scholar
• LarsenSMLevineLAReview of non-surgical treatment options for Peyronie’s diseaseInt J Impot Res201224111021918530
   PubMed Web of Science ®Google Scholar
• HalalAAGeavletePCebanEPharmacological therapy in patients diagnosed with Peyronie’s diseaseJ Med Life20125219219522802890
   PubMedGoogle Scholar
• LevineLAPeyronie’s disease: contemporary review of non-surgical treatmentTransl Androl Urol201321394426816722
   PubMedGoogle Scholar
• PastoriniSMarinoGBrigatoRGriffaDCocimanoVThe therapy of plastic penile induration using superoxide dismutase per os and injection combined with vasoactive intracavernous pharmacotherapyMinerva Urol Nefrol19914327578 Italian1957233
   PubMedGoogle Scholar
• HellstromWJFeldmanRRosenRCSmithTKaufmanGTursiJBother and distress associated with Peyronie’s disease: validation of the Peyronie’s disease questionnaireJ Urol2013190262763423376705
   PubMed Web of Science ®Google Scholar
• BehreHMZitzmannMImaging diagnosticsNieschlagEBehreHMNieschlagSAndrology: Male Reproductive Health and DysfunctionBerlinSpringer-Verlag2010101108
   Google Scholar
• KimCKChoJYProstateKimSHRadiology Illustrated: UroradiologyBerlinSpringer-Verlag2012826
   Google Scholar
• CostantiniTWDereeJPetersonCYPentoxifylline modulates p47phox activation and downregulates neutrophil oxidative burst through PKA-dependent and -independent mechanismsImmunopharmacol Immunotoxicol2010321829119839729
   PubMed Web of Science ®Google Scholar
• FreitasJPFilipePMPentoxifylline. A hydroxyl radical scavengerBiol Trace Elem Res1995471–33073117779563
   PubMed Web of Science ®Google Scholar
• SunilVRVayasKNCervelliJAPentoxifylline attenuates nitrogen mustard-induced acute lung injury, oxidative stress and inflammationExp Mol Pathol2014971899824886962
   PubMed Web of Science ®Google Scholar
• CrouchSPFletcherJEffect of ingested pentoxifylline on neutrophil superoxide anion productionInfect Immun19926011450445091356929
   PubMed Web of Science ®Google Scholar
• GavellaMLipovacVPentoxifylline-mediated reduction of superoxide anion production by human spermatozoaAndrologia199224137391325743
   PubMed Web of Science ®Google Scholar
• JiQZhangLJiaHXuJPentoxifylline inhibits endotoxin-induced NF-kappa B activation and associated production of proinflammatory cytokinesAnn Clin Lab Sci200434442743615648785
   PubMed Web of Science ®Google Scholar
• AnayaJMEspinozaLRPhosphodiesterase inhibitor pentoxifylline: an antiinflammatory/immunomodulatory drug potentially useful in some rheumatic diseasesJ Rheumatol19952245955997791149
   PubMed Web of Science ®Google Scholar
• RussoALongoRVanellaAAntioxidant activity of propolis: role of caffeic acid phenethyl ester and galanginFitoterapia200273Suppl 1S21S2912495706
   PubMed Web of Science ®Google Scholar
• WangXGongGYangWLiYJiangMLiLAntifibrotic activity of galangin, a novel function evaluated in animal liver fibrosis modelEnviron Toxicol Pharmacol201336228829523686009
   PubMed Web of Science ®Google Scholar
• MinYDChoiCHBarkHQuercetin inhibits expression of inflammatory cytokines through attenuation of NF-kappaB and p38 MAPK in HMC-1 human mast cell lineInflamm Res200756521021517588137
   PubMed Web of Science ®Google Scholar
• NakamuraTMatsushimaMHayashiYAttenuation of transforming growth factor-β-stimulated collagen production in fibroblasts by quercetin-induced heme oxygenase-1Am J Respir Cell Mol Biol201144561462021216973
   PubMed Web of Science ®Google Scholar
• RahmanMMIchiyanagiTKomiyamaTHatanoYKonishiTSuper-oxide radical- and peroxynitrite-scavenging activity of anthocyanins; structure-activity relationship and their synergismFree Radic Res2006409993100217015281
   PubMed Web of Science ®Google Scholar
• HouDXYanagitaTUtoTMasuzakiSFujiiMAnthocyanidins inhibit cyclooxygenase-2 expression in LPS-evoked macrophages: structure-activity relationship and molecular mechanisms involvedBiochem Pharmacol200570341742515963474
   PubMed Web of Science ®Google Scholar
• GodboutJPBergBMKrzysztonCJohnsonRWAlpha-tocopherol attenuates NFkappaB activation and pro-inflammatory cytokine production in brain and improves recovery from lipopolysaccharide-induced sickness behaviorJ Neuroimmunol20051691–29710516146653
   PubMed Web of Science ®Google Scholar
• HaasALBoscoboinikDMojonDSBöhnkeMAzziAVitamin E inhibits proliferation of human Tenon’s capsule fibroblasts in vitroOphthalmic Res19962831711758829174
   PubMed Web of Science ®Google Scholar
• FazzioAMarilleyDAzziAThe effect of alpha-tocopherol and beta-tocopherol on proliferation, protein kinase C activity and gene expression in different cell linesBiochem Mol Biol Int1997411931019043639
   PubMedGoogle Scholar
• PaulisGBrancatoTD’AscenzoREfficacy of vitamin E in the conservative treatment of Peyronie’s disease: legend or reality? A controlled study of 70 casesAndrology20131112012823258640
   PubMed Web of Science ®Google Scholar
• ChoJWIlKJLeeKSDownregulation of type I collagen expression in silibinin-treated human skin fibroblasts by blocking the activation of Smad2/3-dependent signaling pathways: potential therapeutic use in the chemoprevention of keloidsInt J Mol Med20133151148115223503720
   PubMed Web of Science ®Google Scholar
• SuraiPFSilymarin as a natural antioxidant: an overview of the current evidence and perspectivesAntioxidants (Basel)20154120424726785346
   PubMedGoogle Scholar
• KimBRSeoHSKuJMSilibinin inhibits the production of pro-inflammatory cytokines through inhibition of NF-κB signaling pathway in HMC-1 human mast cellsInflamm Res2013621194195024045679
   PubMed Web of Science ®Google Scholar
• RongYGengZLauBHGinkgo biloba attenuates oxidative stress in macrophages and endothelial cellsFree Radic Biol Med19962011211278903688
   PubMed Web of Science ®Google Scholar
• HuangCHYangMLTsaiCHLiYCLinYJKuanYHGinkgo biloba leaves extract (EGb 761) attenuates lipopolysaccharide-induced acute lung injury via inhibition of oxidative stress and NF-κB-dependent matrix metalloproteinase-9 pathwayPhytomedicine2013203–430330923219342
   PubMed Web of Science ®Google Scholar
• YaoXChenNMaCHGinkgo biloba extracts attenuate lipopolysaccharide-induced inflammatory responses in acute lung injury by inhibiting the COX-2 and NF-κB pathwaysChin J Nat Med2015131525825660288
   PubMed Web of Science ®Google Scholar
• LiuSQYuJPHeLYuHGLuoHSEffects of nuclear factor kappaB and transforming growth factor beta1 in the anti-liver fibrosis process using Ginkgo biloba extractZhonghua Gan Zang Bing Za Zhi20051312903907 Chinese16381635
   PubMedGoogle Scholar
• LiEGTianJXuZHEffects of Gingko biloba extract (EGb 761) on vascular smooth muscle cell calcification induced by β-glycerophosphateRen Fail201638455255726908182
   PubMed Web of Science ®Google Scholar
• Maffei FacinoRCariniMAldiniGSaibeneLMacciocchiAAntioxidant profile of nimesulide, indomethacin and diclofenac in phosphatidylcholine liposomes (PCL) as membrane modelInt J Tissue React19931562252348088944
   PubMedGoogle Scholar
• RojoCÁlvarez-FigueroaMJSotoMCañeteAPessoa-MahanaDLópez-AlarcónCScavenging activity of diclofenac. Interaction with ABTS radical cation and peroxyl radicalsJ. Chil Chem Soc20095415862
   Web of Science ®Google Scholar
• TangYZLiuZQEvaluation of the free-radical-scavenging activity of diclofenac acid on the free-radical-induced haemolysis of human erythrocytesJ Pharm Pharmacol200658562563116640831
   PubMed Web of Science ®Google Scholar
• NguyenKDLeeDAIn vitro evaluation of antiproliferative potential of topical cyclooxygenase inhibitors in human Tenon’s fibroblastsExp Eye Res1993571971058405177
   PubMed Web of Science ®Google Scholar
• EfeTSagnakERoesslerPPPenetration of topical diclofenac sodium 4% spray gel into the synovial tissue and synovial fluid of the knee: a randomised clinical trialKnee Surg Sports Traumatol Arthrosc201422234535023338668
   PubMed Web of Science ®Google Scholar
• WadsworthLTKentJDHoltRJEfficacy and safety of diclofenac sodium 2% topical solution for osteoarthritis of the knee: a randomized, double-blind, vehicle-controlled, 4 week studyCurr Med Res Opin201632224125026506138
   PubMed Web of Science ®Google Scholar
• PaulisGCombination therapy (in the treatment of Peyronie’s disease)CavalliniGPaulisGPeyronie’s Disease A Comprehensive GuideSwitzerlandSpringer International Publishing201597105
   Google Scholar